← 產業報告目錄

Tranexamic Acid Market Research Report By Formulation Type (Oral Tablets, Injectable Solutions, Topical Applications), By Application (Post-Surgical Bleeding, Menorrhagia, Trauma Cases, Dental Procedures), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End User (Hospitals, Clinics, Home Care Settings), By Dosage Form (Low Dosage, Standard Dosage, High Dosage) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) Forecast to 2035

出版商 Market Research Future產業別 Healthcare & Life Sciences出版日期 2025-03-05頁數 160報告編號 MRFRHC31710HCR

授權報價

Single User Price$4,950 USD
Multi User Licence (up to 10 users)$5,950 USD
Enterprisewide Price (Global Site License)$7,250 USD
洽詢購買 申請 Sample

報告摘要

Tranexamic Acid Market Research Report By Formulation Type (Oral Tablets, Injectable Solutions, Topical Applications), By Application (Post-Surgical Bleeding, Menorrhagia, Trauma Cases, Dental Procedures), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End User (Hospitals, Clinics, Home Care Settings), By Dosage Form (Low Dosage, Standard Dosage, High Dosage) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) Forecast to 2035 Market Overview The Global Tranexamic Acid Market is anticipated to experience substantial growth during the review period, with a compound annual growth rate (CAGR) of 5.38%. It is anticipated that the market will attain a value of USD 1,861.99 million by the conclusion of the forecast period (2025-2035), with an estimated value of USD 1,037.47 million in 2024. The global tranexamic acid market is expanding at a rapid pace, primarily due to the increasing demand for hemostatic agents that are effective in medical, pharmaceutical, and cosmetic applications. Tranexamic acid is being used more frequently to prevent excessive bleeding during surgeries, trauma cases, and menstrual disorders, which is promoting its widespread adoption in hospitals, clinics, home care, and emergency care settings. Furthermore, the market is expanding due to the increasing recognition of the advantages of tranexamic acid in dermatology and cosmetics, particularly for the treatment of hyperpigmentation. The market landscape is being transformed by technological advancements in drug formulations and delivery mechanisms, which have enabled enhanced bioavailability and therapeutic efficacy. Innovative formulations of tranexamic acid, including liposomal and nanoparticle-based formulations, are improving treatment outcomes while diminishing adverse effects. Furthermore, the market is experiencing growth because of the expansion of the scope of tranexamic acid in medical and aesthetic applications through the development of combination therapies that incorporate other active ingredients. Market Segmentation Analysis In 2024, the oral segment held a market share of 47.67% based on Formulation Type and is anticipated to grow at a compound annual growth rate (CAGR) of 5.83% during the forecast period. This is primarily motivated by its broad accessibility, affordability, and convenience. The substantial market share of oral tablets is a result of their widespread prescription for conditions such as excessive menstrual bleeding and surgical bleeding prevention. In 2024, the hospitals & clinics segment held a market share of 45.25% based on End User and is anticipated to grow at a compound annual growth rate (CAGR) of 5.23% during the forecast period. The high volume of surgical procedures, trauma cases, and critical care treatments that necessitate tranexamic acid for hemorrhage management is the reason for this growth. Analysis of the Region In the global tranexamic acid (TXA) market, North America is the dominant region due to its advanced healthcare infrastructure, high volume of surgical procedures, and growing awareness of blood loss management. The United States and Canada have been at the forefront of TXA adoption as a result of the increasing number of trauma-related injuries, supportive regulatory policies, and the expansion of surgical interventions. Europe is a mature and well-regulated TXA market, characterized by pervasive clinical adoption, strong government support, and well-established pharmaceutical manufacturing capabilities. TXA has been certified for a variety of medical applications by the European Medicines Agency (EMA) and national regulatory bodies, thereby guaranteeing standardized usage across healthcare institutions. The Asia-Pacific (APAC) region is experiencing rapid expansion in the tranexamic acid (TXA) market, which is being driven by expanding pharmaceutical production, high trauma incidences, rising maternal healthcare concerns, and increasing surgical volumes. Countries such as Germany are among those in this region. The adoption of TXA is being led by countries such as China, India, Japan, South Korea, and Australia, which are benefiting from an increasing number of clinical applications, growing awareness about blood loss management, and rising healthcare investments. Major Players Pfizer Inc., Fresenius Kabi AG, Teva Pharmaceuticals, Maxwellia Ltd, Aurobindo Pharma, Sun Pharma, Apotex Inc, Ferring Pharmaceuticals, Amring Pharmaceuticals Inc., and Exela Pharma Sciences are among the notable participants in the industry.
目錄 Table of Contents
TABLE OF CONTENTS 1 EXECUTIVE SUMMARY ............................................................................................................... 16 1.1 OVERVIEW .................................................................................................................................................................... 16 1.2 MARKET ATTRACTIVENESS ANALYSIS ........................................................................................................... 18 1.3 GLOBAL TRANEXAMIC ACID MARKET, BY FORMULATION TYPE .......................................................... 19 1.4 GLOBAL TRANEXAMIC ACID MARKET, BY APPLICATION ......................................................................... 20 1.5 GLOBAL TRANEXAMIC ACID MARKET, BY END USER ................................................................................. 21 1.6 GLOBAL TRANEXAMIC ACID MARKET, BY REGION ...................................................................................... 22 2 MARKET INTRODUCTION ............................................................................................................ 24 2.1 DEFINITION .................................................................................................................................................................. 24 2.2 SCOPE OF THE STUDY .............................................................................................................................................. 24 2.3 RESEARCH OBJECTIVE ............................................................................................................................................ 24 2.4 MARKET STRUCTURE .............................................................................................................................................. 24 3 RESEARCH METHODOLOGY ...................................................................................................... 25 3.1 OVERVIEW .................................................................................................................................................................... 25 3.2 DATA FLOW .................................................................................................................................................................. 27 3.2.1 Data Mining Process ....................................................................................................................................... 27 3.3 PURCHASED DATABASE: ......................................................................................................................................... 28 3.4 SECONDARY SOURCES: ............................................................................................................................................ 29 3.4.1 Secondary Research Data Flow: ....................................................................................................................... 30 3.5 PRIMARY RESEARCH: ............................................................................................................................................... 31 3.5.1 Primary Research Data Flow: .......................................................................................................................... 32 3.5.2 Primary Research: Number of Interviews conducted ........................................................................................ 33 3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ........................................................................................... 34 3.6.1 Revenue Analysis Approach ............................................................................................................................ 34 3.7 DATA FORECASTING................................................................................................................................................. 35 3.7.1 Data forecasting Type ..................................................................................................................................... 35 3.8 DATA MODELING ........................................................................................................................................................ 36 3.8.1 Microeconomic Factor Analysis: ...................................................................................................................... 36 3.8.2 Data modeling: ............................................................................................................................................... 37 3.9 TEAMS AND ANALYST CONTRIBUTION ........................................................................................................... 38 4 MARKET DYNAMICS .................................................................................................................... 40 4.1 INTRODUCTION ........................................................................................................................................................... 40 4.2 GROWTH PARAMETERS MAPPED – DRIVERS ................................................................................................ 42 4.2.1 Increasing Surgical Procedures ....................................................................................................................... 42 4.2.2 Growing Prevalence of Trauma Cases .............................................................................................................. 43 4.2.3 Growing Prevalence of Heavy Menstrual Bleeding (HMB) .................................................................................. 43 4.3 WHAT ARE THE CHALLENGES FACED BY INDUSTRY PARTICIPANTS? ............................................... 45 4.3.1 Stringent Regulatory Requirements .................................................................................................................. 45 4.3.2 High R&D Costs for New Formulations ............................................................................................................. 46 4.4 MARKET OPPORTUNITIES MAPPED ................................................................................................................... 47 4.4.1 Rising Demand for Minimally Invasive & Non-Surgical Treatment Options .......................................................... 47 4.4.2 Untapped Potential in Emerging Markets ......................................................................................................... 48 5 MARKET FACTOR ANALYSIS ...................................................................................................... 49 5.1 PORTER’S FIVE FORCES MODEL ........................................................................................................................... 49 5.1.1 Bargaining Power of Suppliers ......................................................................................................................... 49 5.1.2 Bargaining Power of Buyers ............................................................................................................................ 50 5.1.3 Threat of New Entrants ................................................................................................................................... 50 5.1.4 Threat of Substitutes ...................................................................................................................................... 51 5.1.5 Intensity of Rivalry .......................................................................................................................................... 51 5.2 COVID-19 IMPACT ANALYSIS ................................................................................................................................ 52 5.2.1 Impact on R & D .............................................................................................................................................. 52 5.2.2 Impact on Supply Chain .................................................................................................................................. 52 5.2.3 Impact on Pricing ........................................................................................................................................... 53 6 GLOBAL TRANEXAMIC ACID MARKET, BY FORMULATION TYPE ............................................ 55 6.1 INTRODUCTION ........................................................................................................................................................... 55 6.2 ORAL ............................................................................................................................................................................... 57 6.3 INJECTABLE................................................................................................................................................................. 58 6.4 TROPICAL ...................................................................................................................................................................... 59 7 GLOBAL TRANEXAMIC ACID MARKET, BY APPLICATION ........................................................ 61 7.1 INTRODUCTION ........................................................................................................................................................... 61 7.2 MENORRHAGIA ........................................................................................................................................................... 63 7.3 SURGICAL BLEEDING CONTROL ............................................................................................................................ 65 7.4 TRAUMA AND INJURY ............................................................................................................................................ 66 7.5 HEREDITARY ANGIOEDEMA (HAE) ..................................................................................................................... 68 7.6 POSTPARTUM HEMORRHAGE .............................................................................................................................. 69 7.7 OTHERS .......................................................................................................................................................................... 70 8 GLOBAL TRANEXAMIC ACID MARKET, BY END USER ............................................................. 72 8.1 INTRODUCTION ........................................................................................................................................................... 72 8.2 HOSPITALS & CLINICS .............................................................................................................................................. 73 8.3 AMBULATORY SURGICAL CENTERS ................................................................................................................... 75 8.4 OTHERS .......................................................................................................................................................................... 76 9 GLOBAL TRANEXAMIC ACID MARKET, BY REGION.................................................................. 78 9.1 OVERVIEW .................................................................................................................................................................... 78 9.2 NORTH AMERICA ....................................................................................................................................................... 80 9.2.1 US.................................................................................................................................................................. 84 9.2.2 CANADA ........................................................................................................................................................ 85 9.3 EUROPE .......................................................................................................................................................................... 87 9.3.1 GERMANY ...................................................................................................................................................... 91 9.3.2 UK ................................................................................................................................................................. 92 9.3.3 FRANCE ......................................................................................................................................................... 94 9.3.4 ITALY ............................................................................................................................................................. 95 9.3.5 SPAIN ............................................................................................................................................................ 97 9.3.6 REST OF EUROPE ............................................................................................................................................ 98 9.4 ASIA-PACIFIC ............................................................................................................................................................... 100 9.4.1 CHINA ............................................................................................................................................................ 104 9.4.2 INDIA ............................................................................................................................................................. 105 9.4.3 JAPAN ........................................................................................................................................................... 107 9.4.4 SOUTH KOREA ................................................................................................................................................ 108 9.4.5 AUSTRALIA .................................................................................................................................................... 110 9.4.6 REST OF ASIA-PACIFIC ................................................................................................................................... 111 9.5 REST OF THE WORLD ................................................................................................................................................ 113 9.5.1 MIDDLE EAST ................................................................................................................................................. 117 9.5.2 AFRICA .......................................................................................................................................................... 118 9.5.3 LATIN AMERICA ............................................................................................................................................. 120 10 COMPETITIVE LANDSCAPE ........................................................................................................ 123 10.1 INTRODUCTION ........................................................................................................................................................... 123 10.2 MARKET SHARE ANALYSIS, 2024 ....................................................................................................................... 123 10.3 COMPETITION DASHBOARD ................................................................................................................................... 124 10.3.1 PRODUCT PORTFOLIO .................................................................................................................................... 124 10.3.2 REGIONAL PRESENCE ..................................................................................................................................... 125 10.3.3 STRATEGIC ALLIANCES .................................................................................................................................. 125 10.3.4 INDUSTRY EXPERIENCES ................................................................................................................................ 125 10.4 WHO ARE THE MAJOR DISRUPTORS & INNOVATORS ................................................................................. 125 10.5 WHAT STRATEGIES ARE BEING ADOPTED BY MARKET LEADERS ........................................................ 126 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES ............................................................................................ 126 10.6.1 Merger and Acquisition ................................................................................................................................... 126 10.6.2 Product launch ............................................................................................................................................... 127 11 COMPANY PROFILES .................................................................................................................. 128 11.1 PFIZER INC .................................................................................................................................................................... 128 11.1.1 COMPANY OVERVIEW ..................................................................................................................................... 128 11.1.2 FINANCIAL OVERVIEW .................................................................................................................................... 129 11.1.3 PRODUCTS OFFERED ...................................................................................................................................... 129 11.1.4 KEY DEVELOPMENTS ...................................................................................................................................... 130 11.1.5 SWOT ANALYSIS ............................................................................................................................................ 130 11.1.6 Key Strategy ................................................................................................................................................... 130 11.2 FRESENIUS KABI USA, LLC ..................................................................................................................................... 131 11.2.1 COMPANY OVERVIEW ..................................................................................................................................... 131 11.2.2 FINANCIAL OVERVIEW .................................................................................................................................... 132 11.2.3 PRODUCTS OFFERED ...................................................................................................................................... 132 11.2.4 KEY DEVELOPMENTS ...................................................................................................................................... 132 11.2.5 SWOT ANALYSIS ............................................................................................................................................ 133 11.2.6 Key Strategy ................................................................................................................................................... 133 11.3 TEVA PHARMACEUTICAL INDUSTRIES LTD. .................................................................................................. 134 11.3.1 COMPANY OVERVIEW ..................................................................................................................................... 134 11.3.2 FINANCIAL OVERVIEW .................................................................................................................................... 135 11.3.3 PRODUCTS OFFERED ...................................................................................................................................... 135 11.3.4 KEY DEVELOPMENTS ...................................................................................................................................... 135 11.3.5 SWOT ANALYSIS ............................................................................................................................................ 136 11.3.6 Key Strategy ................................................................................................................................................... 136 11.4 MAXWELLIA LTD. ...................................................................................................................................................... 137 11.4.1 COMPANY OVERVIEW ..................................................................................................................................... 137 11.4.2 PRODUCTS OFFERED ...................................................................................................................................... 138 11.4.3 KEY DEVELOPMENTS ...................................................................................................................................... 138 11.4.4 SWOT ANALYSIS ............................................................................................................................................ 139 11.4.5 Key Strategy ................................................................................................................................................... 139 11.5 AUROBINDO PHARMA USA .................................................................................................................................... 140 11.5.1 COMPANY OVERVIEW ..................................................................................................................................... 140 11.5.2 PRODUCTS OFFERED ...................................................................................................................................... 141 11.5.3 KEY DEVELOPMENTS ...................................................................................................................................... 141 11.5.4 SWOT ANALYSIS ............................................................................................................................................ 141 11.5.5 Key Strategy ................................................................................................................................................... 142 11.6 SUN PHARMACEUTICAL INDUSTRIES LTD. ..................................................................................................... 143 11.6.1 COMPANY OVERVIEW ..................................................................................................................................... 143 11.6.2 FINANCIAL OVERVIEW .................................................................................................................................... 144 11.6.3 PRODUCTS OFFERED ...................................................................................................................................... 144 11.6.4 KEY DEVELOPMENTS ...................................................................................................................................... 144 11.6.5 SWOT ANALYSIS ............................................................................................................................................ 145 11.6.6 Key Strategy ................................................................................................................................................... 145 11.7 APOTEX INC. ................................................................................................................................................................ 146 11.7.1 COMPANY OVERVIEW ..................................................................................................................................... 146 11.7.2 PRODUCTS OFFERED ...................................................................................................................................... 147 11.7.3 KEY DEVELOPMENTS ...................................................................................................................................... 147 11.7.4 SWOT ANALYSIS ............................................................................................................................................ 148 11.7.5 Key Strategy ................................................................................................................................................... 148 11.8 FERRING PHARMACEUTICALS ............................................................................................................................. 149 11.8.1 COMPANY OVERVIEW ..................................................................................................................................... 149 11.8.2 PRODUCTS OFFERED ...................................................................................................................................... 150 11.8.3 KEY DEVELOPMENTS ...................................................................................................................................... 150 11.8.4 SWOT ANALYSIS ............................................................................................................................................ 150 11.8.5 Key Strategy ................................................................................................................................................... 151 11.9 NORDIC PHARMA, INC .............................................................................................................................................. 152 11.9.1 COMPANY OVERVIEW ..................................................................................................................................... 152 11.9.2 PRODUCTS OFFERED ...................................................................................................................................... 153 11.9.3 KEY DEVELOPMENTS ...................................................................................................................................... 153 11.9.4 SWOT ANALYSIS ............................................................................................................................................ 153 11.9.5 Key Strategy ................................................................................................................................................... 154 11.10 EXELA PHARMA SCIENCES LLC ........................................................................................................................... 155 11.10.1 COMPANY OVERVIEW ..................................................................................................................................... 155 11.10.2 PRODUCTS OFFERED ...................................................................................................................................... 156 11.10.3 KEY DEVELOPMENTS ...................................................................................................................................... 156 11.10.4 SWOT ANALYSIS ............................................................................................................................................ 156 11.10.5 Key Strategy ................................................................................................................................................... 157 12 DATA CITATIONS ......................................................................................................................... 158
圖表清單 List of Tables & Figures
LIST OF TABLES TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 37 TABLE 2 GLOBAL TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019–2035 (USD MILLION) 56 TABLE 3 GLOBAL TRANEXAMIC ACID MARKET, FOR ORAL, BY REGION, 2019–2035 (USD MILLION) 57 TABLE 4 GLOBAL TRANEXAMIC ACID MARKET, FOR INJECTABLE, BY REGION, 2019–2035 (USD MILLION) 59 TABLE 5 GLOBAL TRANEXAMIC ACID MARKET, FOR TROPICAL, BY REGION, 2019–2035 (USD MILLION) 60 TABLE 6 GLOBAL TRANEXAMIC ACID MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 62 TABLE 7 GLOBAL TRANEXAMIC ACID MARKET, FOR MENORRHAGIA, BY REGION, 2019–2035 (USD MILLION) 64 TABLE 8 GLOBAL TRANEXAMIC ACID MARKET, FOR SURGICAL BLEEDING CONTROL, BY REGION, 2019–2035 (USD MILLION) 66 TABLE 9 GLOBAL TRANEXAMIC ACID MARKET, FOR TRAUMA AND INJURY, BY REGION, 2019–2035 (USD MILLION) 67 TABLE 10 GLOBAL TRANEXAMIC ACID MARKET, FOR HEREDITARY ANGIOEDEMA (HAE), BY REGION, 2019–2035 (USD MILLION) 69 TABLE 11 GLOBAL TRANEXAMIC ACID MARKET, FOR POSTPARTUM HEMORRHAGE, BY REGION, 2019–2035 (USD MILLION) 70 TABLE 12 GLOBAL TRANEXAMIC ACID MARKET, FOR OTHERS, BY REGION, 2019–2035 (USD MILLION) 71 TABLE 13 GLOBAL TRANEXAMIC ACID MARKET, BY END USER, 2019–2035 (USD MILLION) 73 TABLE 14 GLOBAL TRANEXAMIC ACID MARKET, FOR HOSPITALS & CLINICS, BY REGION, 2019–2035 (USD MILLION) 74 TABLE 15 GLOBAL TRANEXAMIC ACID MARKET, FOR AMBULATORY SURGICAL CENTERS, BY REGION, 2019–2035 (USD MILLION) 75 TABLE 16 GLOBAL TRANEXAMIC ACID MARKET, FOR OTHERS, BY REGION, 2019–2035 (USD MILLION) 77 TABLE 17 GLOBAL TRANEXAMIC ACID MARKET, BY REGION, 2019-2035 (USD MILLION) 79 TABLE 18 NORTH AMERICA TRANEXAMIC ACIDS MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 81 TABLE 19 NORTH AMERICA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019–2035 (USD MILLION) 82 TABLE 20 NORTH AMERICA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 83 TABLE 21 NORTH AMERICA: TRANEXAMIC ACID MARKET, BY END USER, 2019–2035 (USD MILLION) 83 TABLE 22 US: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019–2035 (USD MILLION) 84 TABLE 23 US: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 84 TABLE 24 US: TRANEXAMIC ACID MARKET, BY END USER, 2019–2035 (USD MILLION) 85 TABLE 25 CANADA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019–2035 (USD MILLION) 85 TABLE 26 CANADA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 86 TABLE 27 CANADA: TRANEXAMIC ACID MARKET, BY END USER, 2019–2035 (USD MILLION) 86 TABLE 28 EUROPE: TRANEXAMIC ACIDS MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 88 TABLE 29 EUROPE: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019–2035 (USD MILLION) 89 TABLE 30 EUROPE: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 90 TABLE 31 EUROPE: TRANEXAMIC ACID MARKET, BY END USER, 2019–2035 (USD MILLION) 90 TABLE 32 GERMANY: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019–2035 (USD MILLION) 91 TABLE 33 GERMANY: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 91 TABLE 34 GERMANY: TRANEXAMIC ACID MARKET, BY END USER, 2019–2035 (USD MILLION) 92 TABLE 35 UK: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019–2035 (USD MILLION) 92 TABLE 36 UK: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 93 TABLE 37 UK: TRANEXAMIC ACID MARKET, BY END USER, 2019–2035 (USD MILLION) 93 TABLE 38 FRANCE: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019–2035 (USD MILLION) 94 TABLE 39 FRANCE: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 94 TABLE 40 FRANCE: TRANEXAMIC ACID MARKET, BY END USER, 2019–2035 (USD MILLION) 95 TABLE 41 ITALY: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019–2035 (USD MILLION) 95 TABLE 42 ITALY: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 96 TABLE 43 ITALY: TRANEXAMIC ACID MARKET, BY END USER, 2019–2035 (USD MILLION) 96 TABLE 44 SPAIN: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019–2035 (USD MILLION) 97 TABLE 45 SPAIN: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 97 TABLE 46 SPAIN: TRANEXAMIC ACID MARKET, BY END USER, 2019–2035 (USD MILLION) 98 TABLE 47 REST OF EUROPE: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019–2035 (USD MILLION) 98 TABLE 48 REST OF EUROPE: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 99 TABLE 49 REST OF EUROPE: TRANEXAMIC ACID MARKET, BY END USER, 2019–2035 (USD MILLION) 99 TABLE 50 ASIA-PACIFIC: TRANEXAMIC ACID MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 101 TABLE 51 ASIA-PACIFIC: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019–2035 (USD MILLION) 102 TABLE 52 ASIA-PACIFIC: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 103 TABLE 53 ASIA-PACIFIC: TRANEXAMIC ACID MARKET, BY END USER, 2019–2035 (USD MILLION) 103 TABLE 54 CHINA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019–2035 (USD MILLION) 104 TABLE 55 CHINA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 104 TABLE 56 CHINA: TRANEXAMIC ACID MARKET, BY END USER, 2019–2035 (USD MILLION) 105 TABLE 57 INDIA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019–2035 (USD MILLION) 105 TABLE 58 INDIA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 106 TABLE 59 INDIA: TRANEXAMIC ACID MARKET, BY END USER, 2019–2035 (USD MILLION) 106 TABLE 60 JAPAN: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019–2035 (USD MILLION) 107 TABLE 61 JAPAN: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 107 TABLE 62 JAPAN: TRANEXAMIC ACID MARKET, BY END USER, 2019–2035 (USD MILLION) 108 TABLE 63 SOUTH KOREA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019–2035 (USD MILLION) 108 TABLE 64 SOUTH KOREA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 109 TABLE 65 SOUTH KOREA: TRANEXAMIC ACID MARKET, BY END USER, 2019–2035 (USD MILLION) 109 TABLE 66 AUSTRALIA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019–2035 (USD MILLION) 110 TABLE 67 AUSTRALIA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 110 TABLE 68 AUSTRALIA: TRANEXAMIC ACID MARKET, BY END USER, 2019–2035 (USD MILLION) 111 TABLE 69 REST OF ASIA-PACIFIC: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019–2035 (USD MILLION) 111 TABLE 70 REST OF ASIA-PACIFIC: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 112 TABLE 71 REST OF ASIA-PACIFIC: TRANEXAMIC ACID MARKET, BY END USER, 2019–2035 (USD MILLION) 112 TABLE 72 REST OF THE WORLD: TRANEXAMIC ACID MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 114 TABLE 73 REST OF THE WORLD: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019–2035 (USD MILLION) 115 TABLE 74 REST OF THE WORLD: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 116 TABLE 75 REST OF THE WORLD: TRANEXAMIC ACID MARKET, BY END USER, 2019–2035 (USD MILLION) 116 TABLE 76 MIDDLE EAST: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019–2035 (USD MILLION) 117 TABLE 77 MIDDLE EAST: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 117 TABLE 78 MIDDLE EAST: TRANEXAMIC ACID MARKET, BY END USER, 2019–2035 (USD MILLION) 118 TABLE 79 AFRICA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019–2035 (USD MILLION) 118 TABLE 80 AFRICA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 119 TABLE 81 AFRICA: TRANEXAMIC ACID MARKET, BY END USER, 2019–2035 (USD MILLION) 119 TABLE 82 LATIN AMERICA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019–2035 (USD MILLION) 120 TABLE 83 LATIN AMERICA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 120 TABLE 84 LATIN AMERICA: TRANEXAMIC ACID MARKET, BY END USER, 2019–2035 (USD MILLION) 121 TABLE 85 MERGER AND ACQUISITION 126 TABLE 86 PRODUCT LAUNCH 127 TABLE 87 PFIZER INC: PRODUCTS OFFERED 129 TABLE 88 FRESENIUS KABI USA, LLC: PRODUCTS OFFERED 132 TABLE 89 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS OFFERED 135 TABLE 90 MAXWELLIA LTD.: PRODUCTS OFFERED 138 TABLE 91 AUROBINDO PHARMA USA: PRODUCTS OFFERED 141 TABLE 92 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED 144 TABLE 93 APOTEX INC.: PRODUCTS OFFERED 147 TABLE 94 FERRING PHARMACEUTICALS: PRODUCTS OFFERED 150 TABLE 95 NORDIC PHARMA, INC: PRODUCTS OFFERED 153 TABLE 96 EXELA PHARMA SCIENCES LLC: PRODUCTS OFFERED 156 LIST OF FIGURES FIGURE 1 MARKET ATTRACTIVENESS ANALYSIS: GLOBAL TRANEXAMIC ACID MARKET, 2024 18 FIGURE 2 GLOBAL TRANEXAMIC ACID MARKET ANALYSIS, BY FORMULATION TYPE, 2024 19 FIGURE 3 GLOBAL TRANEXAMIC ACID ANALYSIS, BY APPLICATION, 2024 20 FIGURE 4 GLOBAL TRANEXAMIC ACID ANALYSIS, BY END USER, 2024 21 FIGURE 5 GLOBAL TRANEXAMIC ACID MARKET ANALYSIS, BY REGION, 2024 22 FIGURE 1 GLOBAL TRANEXAMIC ACID MARKET: STRUCTURE 24 FIGURE 2 GLOBAL TRANEXAMIC ACID MARKET: MARKET GROWTH FACTOR ANALYSIS (2019-2035) 41 FIGURE 3 DRIVER IMPACT ANALYSIS (2019-2035) 45 FIGURE 4 PORTER’S FIVE FORCES MODEL: GLOBAL TRANEXAMIC ACID MARKET 49 FIGURE 5 GLOBAL TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, SEGMENT ATTRACTIVENESS ANALYSIS 55 FIGURE 6 GLOBAL TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2024 & 2035 (USD MILLION) 56 FIGURE 7 GLOBAL TRANEXAMIC ACID MARKET SHARE (%), BY FORMULATION TYPE, 2024 56 FIGURE 8 GLOBAL TRANEXAMIC ACID MARKET, BY APPLICATION, SEGMENT ATTRACTIVENESS ANALYSIS 61 FIGURE 9 GLOBAL TRANEXAMIC ACID MARKET, BY APPLICATION, 2024 & 2035 (USD MILLION) 62 FIGURE 10 GLOBAL TRANEXAMIC ACID MARKET SHARE (%), BY APPLICATION, 2024 63 FIGURE 11 GLOBAL TRANEXAMIC ACID MARKET, BY END USER, SEGMENT ATTRACTIVENESS ANALYSIS 72 FIGURE 12 GLOBAL TRANEXAMIC ACID MARKET, BY END USER, 2024 & 2035 (USD MILLION) 72 FIGURE 13 GLOBAL TRANEXAMIC ACID MARKET SHARE (%), BY END USER, 2024 73 FIGURE 14 GLOBAL TRANEXAMIC ACID MARKET, BY REGION, 2024 & 2035 (USD MILLION) 79 FIGURE 15 GLOBAL TRANEXAMIC ACID MARKET SHARE (%), BY REGION, 2024 80 FIGURE 16 NORTH AMERICA: TRANEXAMIC ACID MARKET, BY COUNTRY, 2024 & 2035 (USD MILLION) 81 FIGURE 17 NORTH AMERICA: TRANEXAMIC ACID MARKET SHARE (%), BY COUNTRY, 2024 82 FIGURE 18 EUROPE: TRANEXAMIC ACIDS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION) 88 FIGURE 19 EUROPE: TRANEXAMIC ACIDS MARKET SHARE, BY COUNTRY, 2024 (%) 89 FIGURE 20 ASIA-PACIFIC: TRANEXAMIC ACID MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION) 101 FIGURE 21 ASIA-PACIFIC: TRANEXAMIC ACID MARKET SHARE, BY COUNTRY, 2024 (%) 102 FIGURE 22 REST OF THE WORLD: TRANEXAMIC ACID MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION) 114 FIGURE 23 REST OF THE WORLD: TRANEXAMIC ACID MARKET SHARE, BY REGION, 2024 (%) 115 FIGURE 24 GLOBAL TRANEXAMIC ACID MARKET PLAYERS: COMPETITIVE ANALYSIS, 2024 123 FIGURE 25 COMPETITOR DASHBOARD: GLOBAL TRANEXAMIC ACID MARKET 124 FIGURE 26 PFIZER INC: SWOT ANALYSIS 130 FIGURE 27 FRESENIUS KABI USA, LLC: SWOT ANALYSIS 133 FIGURE 28 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS 136 FIGURE 29 MAXWELLIA LTD: SWOT ANALYSIS 139 FIGURE 30 AUROBINDO PHARMA USA: SWOT ANALYSIS 141 FIGURE 31 SUN PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS 145 FIGURE 32 APOTEX INC.: SWOT ANALYSIS 148 FIGURE 33 FERRING PHARMACEUTICALS: SWOT ANALYSIS 150 FIGURE 34 NORDIC PHARMA, INC: SWOT ANALYSIS 153 FIGURE 35 EXELA PHARMA SCIENCES LLC: SWOT ANALYSIS 156

提及公司

Pfizer Inc.Fresenius Kabi AGTeva PharmaceuticalsMaxwellia LtdAurobindo PharmaSun PharmaApotex IncFerring PharmaceuticalsAmring Pharmaceuticals Inc.and Exela Pharma Sciences

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們